A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs

We have generated fusion proteins between vascular endothelial growth factor (VEGF) and the bacterial enzyme carboxypeptidase G2 (CPG2) that can activate the prodrug 4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA). Three asparagine residues of CPG2 were mutated to glutamine (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Spooner, R A, Friedlos, F, Maycroft, K, Stribbling, S M, Roussel, J, Brueggen, J, Stolz, B, O'Reilly, T, Wood, J, Matter, A, Marais, R, Springer, C J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2003
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2377106/
https://ncbi.nlm.nih.gov/pubmed/12771932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600911
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados